COVID Treatment

The risk of long COVID-19 was no worse for patients who had Omicron after the wild-type virus than those just diagnosed with the wild-type.

Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment.

Nightlife transmission of COVID-19 affected a larger number of younger individuals but caused fewer household outbreaks in 2020.

The effectiveness of 2 doses against Omicron infection was highest when the second dose was given in the third trimester of pregnancy compared with the first or second trimesters.

Patients who had relapsed or treatment-resistant cancer at baseline, or those who had more severe acute COVID-19 infections, were less likely to develop long COVID-19.

Results of the ACTIV-6 study showed that high dose ivermectin use did not demonstrate a clinical benefit for mild to moderate COVID-19.

In a subgroup analysis, patients with COVID-19 who received conventional oxygen support also benefitted, having 20 fewer deaths per 1000 patients when given remdesivir.

The findings are the first to explain the mechanisms of any Kawasaki disease, a rare childhood inflammatory condition that is triggered by different viruses.

Arrhythmia was found to be the most common cardiovascular complication of COVID-19.

US adults have a slightly stronger preference for fewer adverse events in relation to pediatric COVID-19 vaccination, study results show.

Relative efficacy of nirmatrelvir–ritonavir appears similar across risk groups, but older adults at risk of severe COVID-19 may benefit more.

Long COVID can impact quality of life, with some symptoms lasting for 1 year before the patient recovers to baseline.

Single nasal swab test can determine whether a patient has COVID-19, influenza, respiratory syncytial virus, or a combination of these viruses in as little as 2 hours.

The test, called VirSNiP SARS-CoV-2 Spike F486P, is for research use only and specifically targets the unique mutation F486P found within the XBB.1.5 Omicron sub-variant.

Increasing efforts have focused on treating COVID-19 among patients in rural areas, who can take advantage of traditional medicines.

Multisystem inflammatory syndrome typically presents approximately 1 month after a COVID infection, occasionally resulting in cardiac complications in previously healthy children.

The therapeutic option is demonstrating favorable results for patients, despite the evolving nature of the SARS-CoV-2 virus.

Data from a recent survey reflect a resounding shift toward the role of pharmacies becoming sites for primary care.

Analysis indicates 4 peptides had significant or nearly significant seropositivity, all of which were associated with membrane and spike proteins of SARS-COVID-2.

COVID-19 infection was significantly associated with increased risks of several conditions, including loss of smell and taste, concentration, and memory impairment.

Providers use "Kitchen Sink Approach" because cure proves elusive, symptomatic treatment is sketchy.

The risk of severe COVID-19 continues to outweigh the rare risk of post-vaccination myocarditis.

An overview of current theses and research surrounding the pathogenesis, presentation, and treatment of COVID-19 in children.

In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.

Pharmacists have been increasingly recognized as key partners in the clinical services needed to manage the pandemic.

Similar symptoms often make it difficult for patients to tell the contagious respiratory conditions apart.

By leveraging do-it-yourself testing momentum, community-based and retail pharmacies can solidify their position as health care hubs with a category management approach that enhances the consumer experience and boosts store relevance and revenue.

Pharmacists concluded that the workflow could be implemented for any drugs that are in short supply.

Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.

Findings support the potential protective association of vaccination in reducing long COVID, although it does not appear to eliminate the risk.